Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 160Head & Neck 41Thoracic 35Breast 34Gynecologic 22Lymphoid 11Sarcoma 10Dermatologic 6CNS 6Other solid neoplasm 4Genitourinary 4Other hematologic neoplasm 3Tumor-Agnostic 2Endocrine 2Other neoplasm 1

Conditions

Urinary Bladder Neoplasms 2Unresectable Gallbladder Cancer 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × camrelizumab × Genitourinary × Clear all
NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Fudan University

Phase 1/2 Active not recruiting
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06423170 2024-05-21

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
37 enrolled
GastrointestinalGenitourinary

Unresectable Gallbladder Cancer

NCT05564897 2022-10-04

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03987698 2020-07-07

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
90 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡